

IN THE CLAIMS

Please amend the claims as follows:

Claims 1-8 (Cancelled)

Claim 9 (Currently Amended): A compound ~~according to claim 1~~ which is:

4-chloro-N-({5-[(2-[(2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]-2-oxoethyl}amino)sulfonyl]thien-2-yl)methyl)benzamide,

4-chloro-N-[(5-[(2-[(2-({5-nitropyridin-2-yl}amino)ethyl)amino]-2-oxoethyl)-amino]sulfonyl]thien-2-yl)methyl]benzamide,

4-chloro-N-({5-[(2-oxo-2-[(2-{[3-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]ethyl}amino)sulfonyl]thien-2-yl)methyl)benzamide,

4-chloro-N-({5-[(2-oxo-2-[(2-{[5-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]ethyl}amino)sulfonyl]thien-2-yl)methyl)benzamide, or

4-chloro-N-[(5-[(2-oxo-2-{3-[(trifluoromethyl)sulfonyl]anilino}ethyl)amino]-sulfonyl]thien-2-yl)methyl]benzamide.

Claims 10-16 (Cancelled).

Claim 17 (Currently Amended): A pharmaceutical composition comprising at least one compound according to claim ~~[[1]]~~ 9 and a pharmaceutically acceptable carrier, diluent or excipient.

Claims 18-28 (Cancelled).

Claim 29 (Currently Amended): ~~The compound according to claim 1, which is 4-chloro-N-({5-[(2-[(2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}ethyl)-amino]-2-oxoethyl}amino)sulfonyl]thien-2-yl}methyl)benzamide.~~

Claim 30 (Currently Amended): A method to treat a disorder of the autoimmune and/or neuronal system comprising
administering the compound of claim 9 [[1]] to a mammal in need thereof in an amount effective to treat a disorder of the autoimmune and/or neuronal system.

Claim 31 (Previously Presented): The method according to claim 30, wherein the mammal is a human.

Claim 32 (Previously Presented): The method of claim 30, wherein the compound is administered orally.

Claim 33 (Currently Amended): A method to treat a disorder of the autoimmune and/or neuronal system comprising
administering the compound of claim 9 [[1]] to a human in an amount effective to down-regulate or inhibit the JNK pathway.

Claim 34 (Previously Presented): The method of claim 30, wherein the compound is administered to a human having at least one neuronal disorder selected from the group consisting of epilepsy, Alzheimer's disease, Huntington's disease, Parkinson's disease, retinal disease, spinal cord injury, and head trauma.

Claim 35 (Previously Presented): The method of claim 30, wherein the compound is administered to a human having at least one autoimmune disease selected from the group consisting of multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, asthma, septic shock, and transplant rejection.

Claims 36-37 (Canceled).

Claim 38 (Previously Presented): The method of claim 30, wherein the compound is administered in an amount effective for decreasing the production of IL-2.

Claims 39-41 (Canceled).

Claim 42 (Currently Amended): A method to treat cancer comprising administering the compound of claim 9 [[1]] to a mammal in need thereof in an amount effective to treat cancer.

Claim 43 (Previously Presented): The method of claim 42, wherein the compound is administered to a human having breast cancer, colorectal cancer, or pancreatic cancer.

Claim 44 (Currently Amended): A method to treat cardiovascular disease comprising administering the compound of claim 9 [[1]] to a mammal in need thereof in an amount effective to treat cardiovascular disease.

Claim 45 (Previously Presented): The method of claim 44, wherein the compound is administered to a human having at least one cardiovascular disease selected from the group

Application No. 10/088,090
Amendment

consisting of stroke arteriosclerosis, myocardial infarction, and myocardial reperfusion injury.